Chemoprophylaxis in gastrointestinal tumors

European Review for Medical and Pharmacological Sciences

Volumn 14, Issue 4, 2010, Pages 285-291

  Zilli, Marinella ^a   Iacobelli, S ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Agent combinations; Chemoprevention; Colorectal cancer; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; ESTROGEN; FOLIC ACID; GESTAGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; SULINDAC; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON ADENOMA; COLON POLYPOSIS; COLORECTAL ADENOMA; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FAMILIAL POLYPOSIS; GASTROINTESTINAL TUMOR; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; NUTRITIONAL SUPPORT; RECTUM POLYP; REVIEW; RISK ASSESSMENT; RISK REDUCTION; VITAMIN SUPPLEMENTATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ASPIRIN; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GASTROINTESTINAL NEOPLASMS; HORMONE REPLACEMENT THERAPY; HUMANS; VITAMINS;

EID: 77953168830     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. JEMAL A, SIEGEL R, WARD E, HAO Y, XU J, MURRAY T, THUN MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. SELBY JV, FRIEDMAN GD, QUESENBERRY CP JR, WEISS NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326: 653-657.
3. KELLOFF GJ. Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 2000; 78: 199-334.
4. GIOVANNUCCI E, RIMM EB, STAMPFER MJ, COLDITZ GA, ASCHERIO A, WILLETT WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241-246.
5. THUN MJ, HENLEY SJ, PATRONO C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-266.
6. EBERHART CE, COFFEY RJ, RADHIKA A, GIARDIELLO FM, FERRENBACH S, DUBOIS RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188.
7. CHAN TA, MORIN PJ, VOGELSTEIN B, KINZLER KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A 1998; 95: 681-686.
8. HANNUN YA. Functions of ceramide in coordinating cellular responses to stress. Science 1996; 274(5294): 1855-1859.
9. SCORRANO L, PENZO D, PETRONILLI V, PAGANO F, BERNARDI P. Arachidonic acid causes cell death through the mitochondrial permeability transition. Implications for tumor necrosis factor-alpha apoptotic signaling. J Biol Chem 2001; 276: 12035-12040.
10. OSHIMA M, DINCHUK JE, KARGMAN SL, OSHIMA H, HANCOCK B, KWONG E, TRZASKOS JM, EVANS JF, TAKETO MM. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-809.
11. CHAN TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 2002; 3: 166-174.
12. YAMAMOTO Y, YIN MJ, LIN KM, GAYNOR RB. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 1999; 274: 27307-27314. (Pubitemid 129520262)
13. HE TC, CHAN TA, VOGELSTEIN B, KINZLER KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335-345.
14. GOLDBERG Y, NASSIF II, PITTAS A, TSAI LL, DYNLACHT BD, RIGAS B, SHIFF SJ. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996; 12: 893-901.
15. RAO CV, REDDY BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004; 4: 29-42.
16. KUNE GA, KUNE S, WATSON LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-4404.
17. GIOVANNUCCI E, RIMM EB, STAMPFER MJ, COLDITZ GA, ASCHERIO A, WILLETT WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994; 121: 241-246.
18. GIOVANNUCCI E, EGAN KM, HUNTER DJ, STAMPFER MJ, COLDITZ GA, WILLETT WC, SPEIZER FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609-614.
19. JACOBS EJ, THUN MJ, BAIN EB, RODRIGUEZ C, HENLEY SJ, CALLE EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99: 608-615.
20. SANDLER RS, HALABI S, BARON JA, BUDINGER S, PASKETT E, KERESZTES R, PETRELLI N, PIPAS JM, KARP DD, LOPRINZI CL, STEINBACH G, SCHILSKY R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-890. (Pubitemid 36297996)
21. BARON JA, COLE BF SANDLER RS, HAILE RW, AHNEN D, BRESALIER R, MCKEOWN-EYSSEN G, SUMMERS RW, ROTHSTEIN R, BURKE CA, SNOVER DC, CHURCH TR, ALLEN JI, BEACH M, BECK GJ, BOND JH, BYERS T, GREENBERG ER, MANDEL JS, MARCON N, MOTT LA, PEARSON L SAIBIL F, VAN STOLK RU. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-899.
22. BENAMOUZIG R, DEYRA J, MARTIN A, GIRARD B, JULLIAN E, PIEDNOIR B, COUTURIER D, COSTE T, LITTLE J, CHAUSSADE S. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003; 125: 328-336.
23. LOGAN RF, GRAINGE MJ, SHEPHERD VC, ARMITAGE NC, MUIR KR; UKCAP TRIAL GROUP. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008; 134: 29-38. (Pubitemid 350309319)
24. COLE BF, LOGAN RF, HALABI S, BENAMOUZIG R, SANDLER RS, GRAINGE MJ, CHAUSSADE S, BARON JA. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009; 101: 256-266.
25. STEINBACH G, LYNCH PM, PHILLIPS RK, WALLACE MH, HAWK E, GORDON GB, WAKABAYASHI N, SAUNDERS B, SHEN Y, FUJIMURA T, SU LK, LEVIN B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952.
26. BARON JA, SANDLER RS, BRESALIER RS, QUAN H, RIDDELL R, LANAS A, BOLOGNESE JA, OXENIUS B, HORGAN K, LOFTUS S, MORTON DG; APPROVE TRIAL INVESTIGATORS. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131: 1674-1682.
27. BERTAGNOLLI MM, EAGLE CJ, ZAUBER AG, REDSTON M, SOLOMON SD, KIM K, TANG J, ROSENSTEIN RB, WITTES J, CORLE D, HESS TM, WOLOJ GM, BOISSERIE F, ANDERSON WF, VINER JL, BAGHERI D, BURN J, CHUNG DC, DEWAR T, FOLEY TR, HOFFMAN N, MACRAE F, PRUITT RE, SALTZMAN JR, SALZBERG B, SYLWESTROWICZ T, GORDON GB, HAWK ET; APC STUDY INVESTIGATORS. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-884.
28. ARBER N, EAGLE CJ, SPICAK J, RÁCZ I, DITE P, HAJER J, ZAVORAL M, LECHUGA MJ, GERLETTI P, TANG J, ROSENSTEIN RB, MACDONALD K, BHADRA P, FOWLER R, WITTES J, ZAUBER AG, SOLOMON SD, LEVIN B; PRESAP TRIAL INVESTIGATORS. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885-895.
29. FITZGERALD GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709-1711.
30. SOLOMON SD, PFEFFER MA, MCMURRAY JJ, FOWLER R, FINN P, LEVIN B, EAGLE C, HAWK E, LECHUGA M, ZAUBER AG, BERTAGNOLLI MM, ARBER N, WITTES J; APC AND PRESAP TRIAL INVESTIGATORS. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006; 114: 1028-1035.
31. WEINGARTEN MA, ZALMANOVICI A, YAPHE J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev 2008; (1): CD003548.
32. GORHAM ED, GARLAND CF, GARLAND FC, GRANT WB, MOHR SB, LIPKIN M, NEWMARK HL, GIOVANNUCCI E, WEI M, HOUCK MF. Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol 2005; 97: 179-194.
33. WACTAWSKI-WENDE J, KOTCHEN JM, ANDERSON GL, ASSAF AR, BRUNNER RL, O'SULLIVAN MJ, MARGOLIS KL, OCKENE JK, PHILLIPS L, POTTERN L, PRENTICE RL, ROBBINS J, ROHAN TE, SARTO GE, SHARMA S, STEFANICK ML, VAN HORN L, WALLACE RB, WHITLOCK E, BASSFORD T, BERESFORD SA, BLACK HR, BONDS DE, BRZYSKI RG, CAAN B, CHLEBOWSKI RT, COCHRANE B, GARLAND C, GASS M, HAYS J, HEISS G, HENDRIX SL, HOWARD BV, HSIA J, HUBBELL FA, JACKSON RD, JOHNSON KC, JUDD H, KOOPERBERG CL, KULLER LH, LACROIX AZ, LANE DS, LANGER RD, LASSER NL, LEWIS CE, LIMACHER MC, MANSON JE; WOMEN'S HEALTH INITIATIVE INVESTIGATORS. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354: 684-696.
34. GORHAM ED, GARLAND CF, GARLAND FC, GRANT WB, MOHR SB, LIPKIN M, NEWMARK HL, GIOVANNUCCI E, WEI M, HOLICK MF. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med 2007; 32: 210-216.
35. GIOVANNUCCI E, STAMPFER MJ, COLDITZ GA, RIMM EB, TRICHOPOULOS D, ROSNER BA, SPEIZER FE, WILLETT WC. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 1993; 85: 875-884.
36. COLE BF, BARON JA, SANDLER RS, HAILE RW, AHNEN DJ, BRESALIER RS, MCKEOWN-EYSSEN G, SUMMERS RW, ROTHSTEIN RI, BURKE CA, SNOVER DC, CHURCH TR, ALLEN JI, ROBERTSON DJ, BECK GJ, BOND JH, BYERS T, MANDEL JS, MOTT LA, PEARSON LH, BARRY EL, REES JR, MARCON N, SAIBIL F, UELAND PM, GREENBERG ER; POLYP PREVENTION STUDY GROUP. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007; 297: 2351-2359.
37. JASZEWSKI R, MISRA S, TOBI M, ULLAH N, NAUMOFF JA, KUCUK O, LEVI E, AXELROD BN, PATEL BB, MAJUMDAR AP. Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial. World J Gastroenterol 2008; 14: 4492-4498.
38. KIM YI. Role of folate in colon cancer development and progression. J Nutr 2003; 133(11 Suppl 1): 3731S-3739S.
39. JOHNSON JR, LACEY JV JR, LAZOVICH D, GELLER MA, SCHAIRER C, SCHATZKIN A, FLOOD A. Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 196-203.
40. CHLEBOWSKI RT, WACTAWSKI-WENDE J, RITENBAUGH C, HUBBELL FA, ASCENSAO J, RODABOUGH RJ, ROSENBERG CA, TAYLOR VM, HARRIS R, CHEN C, ADAMS-CAMPBELL LL, WHITE E; WOMEN'S HEALTH INITIATIVE INVESTIGATORS. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350: 991-1004.
41. MEYSKENS FL JR, MCLAREN CE, PELOT D, FUJIKAWA-BROOKS S, CARPENTER PM, HAWK E, KELLOFF G, LAWSON MJ, KIDAO J, MCCRACKEN J, ALBERS CG, AHNEN DJ, TURGEON DK, GOLDSCHMID S, LANCE P, HAGEDORN CH, GILLEN DL, GERNER EW. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa) 2008; 1: 32-38.